Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy

Journal of Viral Hepatitis

Volumn 17, Issue 3, 2010, Pages 208-216

  Yuan, H J ^a   Jain, M ^a   Snow, K K ^b   Gale Jr , M ^c   Lee, W M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Breakthrough; Chronic hepatitis C; Interferon resistance; Nonstructural 5A protein

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR EVOLUTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TREATMENT RESPONSE; VIRUS GENOME;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CLUSTER ANALYSIS; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHYLOGENY; POLYETHYLENE GLYCOLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, VIRAL; SELECTION, GENETIC; SEQUENCE ANALYSIS, DNA; VIRAL NONSTRUCTURAL PROTEINS;

EID: 75149134314     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01169.x     Document Type: Article

References (41)

1. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 (13 975 982.
2. Hadziyannis SJ, Sette H Jr., Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 (5 346 355.
3. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 (9286 958 965.
4. Yuan HJ, Lee WM. Nonresponse to treatment for hepatitis C: current management strategies. Drugs 2008 68 (1 27 42.
5. Enomoto N, Sakuma I, Asahina Y et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996 334 (2 77 81. (Pubitemid 26017933)
6. Farci P, Shimoda A, Coiana A et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000 288 (5464 339 344.
7. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999 285 (5424 107 110.
8. Gale M Jr., Blakely CM, Kwieciszewski B et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998 18 (9 5208 5218.
9. Paterson M, Laxton CD, Thomas HC, Ackrill AM, Foster GR. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology 1999 117 (5 1187 1197.
10. Podevin P, Sabile A, Gajardo R et al. Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR-independent manner. Hepatology 2001 33 (6 1503 1511.
11. Tsai YH, Kuang WF, Lu TY et al. The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism. J Hepatol 2008 49 (6 899 907.
12. Germanidis G, Metallidis S, Lazaraki G, Pawlotsky JM, Nikolaidis P. NS5A sequences of hepatitis C virus genotype 1 and interferon resistance: where are we? J Infect Dis 2008 198 (1 154 155.
13. Vuillermoz I, Khattab E, Sablon E et al. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy. J Med Virol 2004 74 (1 41 53.
14. Polyak SJ, McArdle S, Liu SL et al. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J Virol 1998 72 (5 4288 4296.
15. Zeuzem S, Lee JH, Roth WK. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 1997 25 (3 740 744.
16. Farci P, Strazzera R, Alter HJ et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 2002 99 (5 3081 3086.
17. Shiffman ML, Ghany MG, Morgan TR et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007 132 (1 103 112.
18. Lee WM, Dienstag JL, Lindsay KL et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004 25 (5 472 492.
19. Morishima C, Morgan TR, Everhart JE et al. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology 2006 44 (2 360 367.
20. McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002 123 (4 1061 1069.
21. Di Bisceglie AM, Shiffman ML, Everson GT et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008 359 (23 2429 2441.
22. Shiffman ML, Di Bisceglie AM, Lindsay KL et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004 126 (4 1015 1023.
23. Nousbaum J, Polyak SJ, Ray SC et al. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol 2000 74 (19 9028 9038.
24. Murphy MD, Rosen HR, Marousek GI, Chou S. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci 2002 47 (6 1195 1205.
25. Tan SL, Nakao H, He Y et al. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci USA 1999 96 (10 5533 5538.
26. He Y, Nakao H, Tan SL et al. Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. J Virol 2002 76 (18 9207 9217.
27. Tan SL, Katze MG. How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virol 2001 284 (1 1 12.
28. Berg T, Sarrazin C, Herrmann E et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003 37 (3 600 609.
29. Donlin MJ, Cannon NA, Yao E et al. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol 2007 81 (15 8211 8224.
30. Boulestin A, Sandres-Saune K, Payen JL, Rostaing L, Pasquier C, Izopet J. Genetic heterogeneity of the NS5A gene of hepatitis C virus and early response to interferon-alpha. J Infect Dis 2003 188 (9 1367 1370.
31. Dal Pero F, Tang KH, Gerotto M et al. Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon-alpha 2a plus ribavirin. J Infect Dis 2007 196 (7 998 1005.
32. Bowen DG, Walker CM. The origin of quasispecies: cause or consequence of chronic hepatitis C viral infection? J Hepatol 2005 42 (3 408 417.
33. Gale M Jr., Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005 436 (7053 939 945.
34. Duverlie G, Khorsi H, Castelain S et al. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol 1998 79 (Pt 6 1373 1381.
35. Fukuda R, Ishimura N, Hamamoto S et al. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. J Med Virol 2001 63 (3 220 227.
36. Mizukoshi E, Kaneko S, Yanagi M et al. Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patients. J Med Virol 1998 56 (3 217 223.
37. Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004 85 (Pt 9 2485 2502.
38. Tellinghuisen TL, Foss KL, Treadaway JC, Rice CM. Identification of residues required for RNA replication in domains II and III of the hepatitis C virus NS5A protein. J Virol 2008 82 (3 1073 1083.
39. Brass V, Pal Z, Sapay N et al. Conserved determinants for membrane association of nonstructural protein 5A from hepatitis C virus and related viruses. J Virol 2007 81 (6 2745 2757.
40. Moradpour D, Evans MJ, Gosert R et al. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J Virol 2004 78 (14 7400 7409.
41. Xu Z, Fan X, Xu Y, Di Bisceglie AM. Comparative analysis of nearly full-length hepatitis C virus quasispecies from patients experiencing viral breakthrough during antiviral therapy: clustered mutations in three functional genes, E2, NS2, and NS5a. J Virol 2008 82 (19 9417 9424.